Solomon Moshkevich, who serves as President, Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), completed the sale of 3,000 shares of the company’s common stock on April 1, 2026, in transactions that together produced about $606,899 in proceeds.
The disposal was carried out in three separate trades. One block of 1,048 shares was sold at a weighted average price of $201.32 per share, a second block of 1,000 shares at $202.36 per share, and a final block of 952 shares at $203.31 per share. Since those transactions, the company’s share price has risen to $207.98, which the company’s data shows represents a 13.9% increase over the past week.
The sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan that was adopted on November 26, 2024. Following the April 1 transactions, Moshkevich is recorded as directly owning 147,882 shares of Natera, Inc.
Market commentary included in the transactional context notes that the $29.5 billion diagnostics company is trading above its InvestingPro Fair Value, an indicator that the stock may be priced above that valuation benchmark. InvestingPro Tips also flag notable price volatility in the shares, and analysts accessible to subscribers are cited as providing additional valuation and growth context.
Alongside the insider sale, Natera disclosed a series of business and corporate developments. The company has introduced Zenith genomics, a whole genome sequencing test developed in collaboration with MyOme that uses long-read sequencing to improve detection of rare genetic conditions. In clinical assay news, Natera’s Signatera circulating tumor DNA test has shown promising findings in studies focused on anal and rectal cancers.
On the governance front, the company expanded its board of directors with the addition of Eric Rubin, bringing the board’s membership to eleven. Separately, Morgan Stanley adjusted its price target for Natera to $250 from $265 while retaining an Overweight rating; the bank’s change followed the company’s fourth-quarter results and was derived from a discounted cash flow analysis.
These items - the insider transaction under an established trading plan, the company’s product advances and clinical data, the board enlargement, and the analyst price-target revision - form the factual backdrop to the reported sales. The company’s recent share-price appreciation and noted volatility are also part of the current market picture.